Dexcom Inc. has gained a new diabetes management platform with the acquisition of TypeZero Technologies, a developer of algorithms that orchestrate insulin dosing with blood glucose monitoring data in an artificial pancreas (AP) system. Terms of the acquisition were not disclosed.
TypeZero's InControl platform emerged from the labs of the University of Virginia's Center for Diabetes Technology. It features a smartphone app that acts as "the little mathematical brain" – as described by TypeZero's Chief Mathematician Boris Kovatchev on the company website – that wirelessly links a continuous glucose monitor (CGM) to a insulin pump, and automatically directs and adjusts insulin delivery based on the patient's current blood glucose status
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?